advertisement
Abstract #11298 Published in IGR 6-3
Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: Three-month comparison of efficacy and safety
Martinez De La Casa JM; Castillo A; Garcia Feijoo J; Mendez Hernandez C; Fernandez Vidal A; Garcia Sanchez JCurrent Medical Research and Opinion 2004; 20: 1333-1339
PURPOSE: To compare the efficacy and safety of the concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily with those of a fixed combination of latanoprost 0.005%/timolol 0.5% once daily. Research, design and METHODS: Forty-four patients with primary open-angle glaucoma or ocular hypertension with elevated IOP insufficiently responsive to monotherapy were randomly assigned to one of the two treatment groups: concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily (TB group: 22 patients) or latanoprost 0.005% plus timolol 0.5% once daily (LT group: 22 patients). Visits were undertaken at screening (current ocular hypotensive therapy was discontinued), baseline (randomization), and after 2 weeks, 1 month, 2 months and 3 months of therapy. Main outcome measures: IOP was determined at 9 a.m., 12 p.m. and 4 p.m. at each study visit, and diurnal IOP was calculated as the mean of these recordings. Adverse events were recorded at each visit. RESULTS: IOP at the baseline visit was similar in both groups. Overall mean IOP was significantly lower in the TB as compared to the LT group after 1 month, 2 month and 3 month follow-up; only 9 a.m. measurements were significantly different, reaching a maximum difference (16.9 ± 0.9 mmHg vs 18.4 ± 1.8 mmHg, p < 0.001) at the 3 month check. The percentage of respondent (IOP decrease ≥ 30%) was higher in the TB group. Both treatments were well tolerated and there were no cases of withdrawal from treatment. CONCLUSIONS: Travoprost 0.004% and brinzolamide 0.1% concomitant therapy showed a greater efficacy than the fixed latanoprost 0.005%/timolol 0.5% combination in terms of absolute IOP decreases. Travoprost/brinzolamide therapy also offered the advantages of a greater percentage of responders.
Dr. J.M. Martinez De La Casa, Cavanilles 33 3a, 28007 Madrid, Spain
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
